Effectiveness of Ziprasidone for Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Ziprasidone

100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.

Trial Locations (6)

425-707

Korea University Medical Center Ansan Hospital, Ansan

420-767

Soonchunhyang University Bucheon Hospital, Bucheon-si

400-700

Inha University Hospital, Incheon

403-720

Catholic University Our Lady of Mercy Hospital, Incheon

152-703

Korea University Medical Center Guro Hospital, Seoul

431-070

Kangnam Sacred Heart Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Soonchunhyang University Hospital

OTHER